Results 61 to 70 of about 19,804 (260)

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić   +7 more
wiley   +1 more source

Population Pharmacokinetic/Pharmacodynamic Analysis of the DPP-4 Inhibitor Linagliptin in Japanese Patients with Type 2 Diabetes Mellitus

open access: yesJournal of Pharmacy & Pharmaceutical Sciences, 2013
[Objectives] Linagliptin is a novel, highly selective and long acting DPP-4 inhibitor for the treatment of type 2 diabetes mellitus (T2DM). Linagliptin exhibits non-linear pharmacokinetics (PK) due to saturable binding to plasma and tissue DPP-4. The aim
Yusuke Tadayasu   +7 more
doaj   +1 more source

Exposure‐adjusted safety and efficacy of GLP‐I and GLP‐1/GIP receptor agonists compared with non‐GLP‐I for weight management and type 2 diabetes: Based on FDA medical and statistical reports of 34 280 safety and 36 312 efficacy subjects

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims This work aimed to contextualize glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and glucose‐dependent insulinotropic polypeptide (GIP) receptor agonists safety and efficacy regarding weight management (WM); we analysed Food and Drug Administration (FDA) Medical Reviews to analyse 14 medications using patient‐exposure year normalization and ...
Aishwarya Prasad   +4 more
wiley   +1 more source

Safety outcomes of antidiabetic medications: A comprehensive review of the EU summaries of product characteristics and international clinical practice guidelines

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Information on the safety profile of antidiabetic medications is essential for informed treatment decisions in type 2 diabetes mellitus. Although this information is available in regulatory documents of individual drugs, a comprehensive overview across all approved antidiabetics is lacking.
David Liang   +5 more
wiley   +1 more source

Purification of Advanced Therapeutics by Flow‐Through Pseudo‐Affinity Chromatography: Bi‐Specific mABs, Fc Fusion Proteins, and Adeno‐Associated Viruses

open access: yesBiotechnology and Bioengineering, EarlyView.
ABSTRACT Modern biopharmaceutical manufacturing requires purification platforms capable of processing structurally and functionally diverse products while addressing the challenge of removing persistent and high‐risk host cell proteins (HCPs).
Wenning Chu   +23 more
wiley   +1 more source

STUDI IN SILICO POTENSI SENYAWA ALLIIN BAWANG PUTIH (Allium sativum) SEBAGAI INHIBITOR DPP-4 PADA DIABETES MELLITUS

open access: yesJurnal Ilmiah Medicamento, 2018
Diabetes mellitus (DM) merupakan penyakit gangguan metabolisme glukosa yang dicirikan dengan gangguan sekresi dan resistensi insulin. Jalur pengobatan DM baru pada sistem increatin dengan penghambatan terhadap DPP-4 telah dikembangkan dan terbukti ...
Martina Kurnia Rohmah
doaj   +5 more sources

Concomitant Use of DPP‐4 Inhibitors May Prevent the Development of Oxaliplatin‐Induced Peripheral Neuropathy: A Retrospective Cohort Study

open access: yesClinical and Translational Science
Oxaliplatin‐induced peripheral neuropathy (OIPN) causes numbness and pain in the limbs, often leading to interruption of chemotherapy and representing a significant clinical problem.
Yusuke Koura   +9 more
doaj   +1 more source

Atomically precise metal cluster enzymes for pathological tissue regeneration

open access: yesBMEMat, EarlyView.
Schematic illustration of atomically precise metal cluster enzymes (MCEs) for pathological tissue regeneration. Atomically precise MCEs can modulate biological processes, such as attenuation of inflammatory responses, eradication of bacterial pathogens, regulation of angiogenesis, and promotion of cell development.
Ziqiang Xiong   +11 more
wiley   +1 more source

Association of DPP-4 inhibitors with respiratory and cardiovascular complications in patients with COPD: a nationwide cohort study

open access: yesERJ Open Research
Aims COPD is a comorbid condition often associated with type 2 diabetes (T2D) and cardiovascular diseases, but few studies have observed the impact of various antidiabetic drugs in patients with COPD and T2D.
Fu-Shun Yen   +7 more
doaj   +1 more source

Homologous tumor‐targeting biomimetic nanozyme for synergistic NIR‐II photothermal and chemodynamic therapy

open access: yesBMEMat, EarlyView.
Studies reveal that a biomimetic nanoplatform based on a cancer cell membrane‐camouflaged Au‐MnOx nanozyme (Au‐MnOx@CCM) can achieve synergistic antitumor therapy by combining NIR‐II mediated PTT with enhanced CDT, offering a promising strategy for precise and efficient tumor therapy. Abstract The therapeutic potential of nanozyme‐mediated chemodynamic
Xiaonan Li   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy